Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...

Age-Related Hearing Loss (ARHL) is a prevalent condition affecting a significant portion of the elderly population worldwide. It is characterized by a ...

Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be present ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...